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Abstract
Background: Schizophrenia is the collective term for an exclusively clinically diagnosed, heterogeneous group of
mental disorders with still obscure biological roots. Based on the assumption that valuable information about
relevant genetic and environmental disease mechanisms can be obtained by association studies on patient cohorts
of ≥1000 patients, if performed on detailed clinical datasets and quantifiable biological readouts, we generated a
new schizophrenia data base, the GRAS (Göttingen Research Association for Schizophrenia) data collection. GRAS is
the necessary ground to study genetic causes of the schizophrenic phenotype in a ‘phenotype-based genetic
association study’ (PGAS). This approach is different from and complementary to the genome-wide association
studies (GWAS) on schizophrenia.
Methods: For this purpose, 1085 patients were recruited between 2005 and 2010 by an invariable team of
traveling investigators in a cross-sectional field study that comprised 23 German psychiatric hospitals. Additionally,
chart records and discharge letters of all patients were collected.
Results: The corresponding dataset extracted and presented in form of an overview here, comprises biographic
information, disease history, medication including side effects, and results of comprehensive cross-sectional
psychopathological, neuropsychological, and neurological examinations. With >3000 data points per schizophrenic
subject, this data base of living patients, who are also accessible for follow-up studies, provides a wide-ranging and
standardized phenotype characterization of as yet unprecedented detail.
Conclusions: The GRAS data base will serve as prerequisite for PGAS, a novel approach to better understanding
‘the schizophrenias’ through exploring the contribution of genetic variation to the schizophrenic phenotypes.
Background
Schizophrenia is a devastating brain disease that affects
approximately 1% of the population across cultures [1].
The diagnosis of schizophrenia or - perhaps more correctly
-o f‘the schizophrenias’ is still purely clinical, requiring the
coincident presence of symptoms as listed in the leading
classification systems, DSM-IV and ICD-10 [2,3].
Notably, one of the core symptoms of schizophrenia,
namely cognitive deficits, from mild impairments to
full-blown dementia, has not yet been considered in
these classifications. Biologically, schizophrenia is a
‘mixed bag’ of diseases that undoubtedly have a strong
genetic root. Family studies exploring relative risk of
schizophrenia have led to estimates of heritability of
about 64-88% [4,5]. Monozygotic twin studies showing
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any medium, provided the original work is properly cited.concordance rates of 41-65% [6,7] indicate a considerable
amount of non-genetic causes, in the following referred
to as ‘environmental factors’. Already in the middle of
the twentieth century, schizophrenia was seen as a ‘poly-
genetic’ disease [8] and, indeed, in numerous genetic stu-
dies since, ranging from segregation or linkage analyses,
genome scans and large association studies, no major
‘schizophrenia gene’ has been identified [9]. Even recent
genome-wide association studies (GWAS) on schizophre-
nia confirm that several distinct loci are associated with
the disease. These studies concentrated on endpoint
diagnosis and found odds ratios for single markers in dif-
ferent genomic regions ranging from 0.68 to 6.01 [10],
essentially underlining the fact that - across ethnicities -
in most cases these genotypes do not contribute more to
the disease than a slightly increased probability.
We hypothesize that an interplay of multiple causative
factors, perhaps thousands of potential combinations of
genes/genetic markers and an array of different environ-
mental risks, leads to the development of ‘the schizo-
phrenias’, as schematically illustrated in Figure 1. There
may be cases with a critical genetic load already present
without need of additional external co-factors, however,
in most individuals, an interaction of a certain genetic
predisposition with environmental co-factors is appar-
ently required for disease onset. In fact, not too much
of an overlap may exist between genetic risk factors
from one schizophrenic patient to an unrelated other
schizophrenic individual, explaining why it is basically
impossible to find common risk genes of schizophrenia
with appreciable odds ratios. One GRAS working
hypothesis is that in the overwhelming majority of cases,
schizophrenia is the result of a ‘combination of unfortu-
nate genotypes’.
If along the lines of traditional human genetics all
attempts to define schizophrenia as a ‘classical’ genetic
disease have largely failed, how can we learn more about
the contribution of genes/genotypes to the disease phe-
notype? Rather than searching by GWAS for yet other
schizophrenia risk genes, we designed an alternative and
widely complementary approach, termed PGAS (pheno-
type-based genetic association study), in order to
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Figure 1 Schizophrenia is a complex multigenetic disease. Schizophrenia may be seen as the result of a multifaceted interplay between
multiple causative factors, including several genetic markers and a variety of different environmental risks. Cases with a critical genetic load may
not need additional external/environmental co-factors, whilst in others, the interaction of a certain genetic predisposition with environmental co-
factors is required for disease onset (modified from [84]).
Ribbe et al. BMC Psychiatry 2010, 10:91
http://www.biomedcentral.com/1471-244X/10/91
Page 2 of 20explore the contribution of certain genes/genetic mar-
kers to the schizophrenic phenotype. To launch PGAS,
we had to establish a comprehensive phenotypical data
base of schizophrenic patients, the GRAS (Göttingen
Research Association for Schizophrenia) data collection.
Very recently, we have been able to demonstrate proof-
of-concept for the PGAS approach [[11], and Grube
et al: Calcium-activated potassium channels as regulators
of cognitive performance in schizophrenia, submitted].
Large data bases of schizophrenic patients have been
instigated for decades to perform linkage/family studies,
treatment trials, genetic or epidemiological studies
applying either a cross-sectional or a longitudinal design
(e.g. [12-20]). However, for the above introduced PGAS
approach, another type of data base is required, and
only few of the existing data banks are suited for pheno-
typical analyses. An example is the ‘Clinical Antipsycho-
tic Trial of Intervention Effectiveness (CATIE)’,
originally set up as a treatment study comparing a first
generation antipsychotic drug with several second gen-
eration antipsychotics in a multisite randomized double-
blind trial [17,21]. The huge amount of data accumu-
lated in the frame of this trial serves now also for
GWAS and genotype-phenotype association studies
[22-25]. Disadvantages mayb et h a tt h eC A T I Ed a t a
were collected by different examiners in 57 US sites and
that comprehensive data for phenotypical analyses are
only available for subsamples of the originally included
1493 patients. Another example of a large data base
with considerable phenotypical power is the ‘Australian
Schizophrenia Research Bank (ASRB)’ [26]. ASRB oper-
ates to collect, store and distribute linked clinical, cogni-
tive, neuroimaging and genetic data from a large sample
of patients with schizophrenia (at present nearly 500)
and healthy controls (almost 300) [27,28]).
The present paper has been designed (1) to introduce
the GRAS data collection, set up as prerequisite and
platform for PGAS; (2) to exemplify on some selected
areas of interest the potential of phenotypical readouts
derived from the GRAS data collection and their inter-
nal consistency; (3) to provide a first panel of epidemio-
logical data as a ‘side harvest’ of this data base; and (4)
to enable interested researchers worldwide to initiate
scientific collaborations based on this data base.
Methods
Ethics
The GRAS data collection has been approved by the ethical
committee of the Georg-August-University of Göttingen
(master committee) as well as by the respective local regu-
latories/ethical committees of all collaborating centers
(Table 1). The distribution of the centers over Germany
together with information on the numbers of recruited
patients per center is presented in Figure 2.
GRAS patients
From September 2005 to July 2008, a total of 1071
patients were examined by the GRAS team of traveling
investigators after giving written informed consent, own
and/or authorized legal representatives. Since then, low-
rate steady state recruitment has been ongoing, among
others to build up a new cohort for replicate analyses of
genotype-phenotype associations. As of July 2010, 1085
patients have been entered into the data base. They
were examined in different settings: 348 (32.1%) as out-
patients, 474 (43.7%) as inpatients in psychiatric hospi-
tals, 189 (17.4%) as residents in sheltered homes, 54
(5%) as patients in specific forensic units, and 20 (1.8%)
a sd a yc l i n i cp a t i e n t s .I n c l u s i o nc r i t e r i aw e r e( 1 )c o n -
firmed or suspected diagnosis of schizophrenia or schi-
zoaffective disorder according to DSM-IV and (2) at
least some ability to cooperate. Recruitment efficiency
over the core travel/field study time from 2005 to 2008
and patient flow are shown in Figures 3a and 3b. Of the
1085 patients entered into the data base, a total of 1037
fulfilled the diagnosis of schizophrenia or schizoaffective
disorder. For 48 patients the diagnosis of schizophrenia
could not be ultimately confirmed upon careful re-check
and follow-up. Of the schizophrenic patients, 96% com-
pleted the GRAS assessment whereas about 4% dropped
out during the examination. Almost all patients agreed
to be re-contacted for potential follow-up studies, only
1.5% were either lost to follow-up (present address
unknown or deceased) or did not give consent to be
contacted again.
Healthy control subjects
(1) For genetic analyses, control subjects, who gave writ-
ten informed consent, were voluntary blood donors,
recruited by the Department of Transfusion Medicine at
the Georg-August-University of Göttingen according to
national guidelines for blood donation. As such, they
widely fulfill health criteria, ensured by a broad pre-
donation screening process containing standardized
questionnaires, interviews, hemoglobin, blood pressure,
pulse, and body temperature determinations. Of the
total of 2265 subjects, 57.5% are male (n = 1303) and
42.5% female (n = 962). The average age is 33.8 ± 12.2
years, with a range from 18 to 69 years. Participation as
healthy controls for the GRAS sample was anonymous,
with information restricted to age, gender, blood donor
health state and ethnicity. Comparable to the patient
population (Table 2), almost all control subjects were of
European Caucasian descent (Caucasian 97.8%; other
ethnicities 2%; unknown 0.2%). (2) For selected cognitive
measures and olfactory testing, 103 additional healthy
volunteers were recruited as control subjects (matched
with respect to age, gender, and smoking habits). These
healthy controls include 67.0% male (n = 69) and 33.0%
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Page 3 of 20Table 1 GRAS data collection manual: Table of contents
category content reference in the paper
legal documents/ethical requirements patient information, informed consent form, confidentiality form, and others...
patient history general information (age, sex, ethnicity,...) ® table 2
education/employment ® table 2
living situation ® table 2
legal history
medication including side effects ® table 4
medical history
family history
global quality of life
a ® table 2 and figure 6
birth history/traumatic brain injury
stressful life events
suicidal thoughts/suicide attempts
hospitalization history ® table 2 and figure 6
clinical interviews/ratings parts of SCID-I: addiction, anxiety, affective disorders, psychotic disorders*
b
Positive and Negative Syndrome Scale* (PANSS)
c ® table 2 and figure 6
Clinical Global Impression* (CGI)
d ® table 2 and figure 6
Global Assessment of Functioning* (GAF)
e ® table 2 and figure 6
questionnaires State-Trait-Anxiety-Inventory* (STAI)
f ® table 2 and figure 6
Brief Symptom Inventory* (BSI)
g ® table 2 and figure 6
Toronto Alexithymia Scale* (TAS)
h ® table 2
cognitive tests premorbid IQ (MWT-B)
i, j ® table 3 and figure 7
reasoning (LPS-3)
k ® table 3 and figure 7
letter-number-span (BZT)
l ® table 3 and figure 7
finger dotting and tapping
m ® table 3 and figure 7
trail making tests (TMT-A and TMT-B)
n ® table 3 and figure 7
verbal fluency (DT/RWT)
o, p
digit-symbol test (ZST)
q ® table 3 and figure 7
verbal memory* (VLMT)
r ® table 3 and figure 7
physical examination Testbatterie zur Aufmerksamkeitsprüfung (TAP)
s ® table 3 and figure 7
general physical examination
Cambridge Neurological Inventory (CNI)
t ® table 5 and figure 8
Contralateral Co-Movement Test (COMO)
u
Barnes Akathisia Rating Scale (BARS)
v ® figure 8
Simpson-Angus Scale (SAS)
w ® figure 8
Tardive Dyskinesia Rating Scale (TDRS)
x ® figure 8
Abnormal Involuntary Movement Scale (AIMS)
y ® figure 8
odor testing (ORNI Test)
z
blood sampling (DNA, serum)
*questionnaires and cognitive tests in respective German versions
a Based on a visual analogue scale (Krampe H, Bartels C, Victorson D, Enders CK, Beaumont J, Cella D, Ehrenreich H: The influence of personality factors on disease progression
and health-related quality of life in people with ALS. Amyotroph Lateral Scler 2008, 9:99-107).
bWittchen H-U, Zaudig, M. and Fydrich, T.: SKID-I (Strukturiertes Klinisches
Interview für DSM-IV; Achse I: Psychische Störungen). Göttingen: Hogrefe; 1997.
cKay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for
schizophrenia. Schizophr Bull 1987, 13(2):261-276.
dGuy W: Clinical Global Impression (CGI). In ECDEU Assessment manual for psychopharmacology, revised National Institue of
Mental Health. Rockville, MD; 1976.
eAmericanPsychiatricAssociation: Diagnostic and statistical manual of mental disorders, 4th edition (DSM-IV). Washington, DC: American
Psychiatric Press; 1994.
fLaux L, Glanzmann P, Schaffner P, Spielberger CD: Das State-Trait-Angstinventar (STAI). Weinheim: Beltz; 1981.
gFranke GH: Brief Symptom Inventory
(BSI). Goettingen: Beltz; 2000.
hKupfer J, Brosig B, Braehler E: Toronto Alexithymie-Skala-26 (TAS-26). Goettingen: Hogrefe; 2001.
iLehrl S, Triebig G, Fischer B: Multiple choice
vocabulary test MWT as a valid and short test to estimate premorbid intelligence. Acta Neurol Scand 1995, 91(5):335-345.
jLehrl S: Mehrfach-Wortschatz-Intelligenztest MWT-B.
Balingen: Spitta Verlag; 1999.
kHorn W: Leistungsprüfsystem (LPS). 2 edition. Goettingen: Hogrefe; 1983.
lGold JM, Carpenter C, Randolph C, Goldberg TE, Weinberger DR:
Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry 1997, 54(2):159-165.
mChapman RL: The MacQuarrie test for
mechanical ability. Psychometrika 1948, 13(3):175-179.
nWar-Department: Army Individual Test Battery. Manual of directions and scoring. Washington, D.C.: War Department,
Adjutant General’s Office; 1944.
oKessler J, Denzler P, Markowitsch HJ: Demenz-Test (DT). Göttingen: Hogrefe; 1999.
pAschenbrenner S, Tucha O, Lange KW: Der Regensburger
Wortflüssigkeits-Test (RWT). Göttingen: Hogrefe; 2000.
qTewes U: Hamburg-Wechsler Intelligenztest fuer Erwachsene (HAWIE-R). Bern: Huber; 1991.
rHelmstaedter C, Lendt M,
Lux S: Verbaler Lern- und Merkfåhigkeitstest (VLMT). Goettingen: Beltz; 2001.
sZimmermann P, Fimm B: Testbatterie zur Aufmerksamkeitsprüfung (TAP). Version 1.02c.
Herzogenrath: PSYTEST; 1993.
tChen EY, Shapleske J, Luque R, McKenna PJ, Hodges JR, Calloway SP, Hymas NF, Dening TR, Berrios GE: The Cambridge Neurological Inventory:
a clinical instrument for assessment of soft neurological signs in psychiatric patients. Psychiatry Res 1995, 56(2):183-204.
uBartels C, Mertens N, Hofer S, Merboldt KD, Dietrich J,
Frahm J, Ehrenreich H: Callosal dysfunction in amyotrophic lateral sclerosis correlates with diffusion tensor imaging of the central motor system. Neuromuscul Disord 2008, 18
(5):398-407.
vBarnes TR: The Barnes Akathisia Rating Scale - revisited. J Psychopharmacol 2003, 17(4):365-370.
wSimpson GM, Angus JW: A rating scale for extrapyramidal side
effects. Acta Psychiatr Scand Suppl 1970, 212:11-19.
xSimpson GM, Lee JH, Zoubok B, Gardos G: A rating scale for tardive dyskinesia. Psychopharmacology (Berl) 1979, 64
(2):171-179.
yGuy W: Abnormal involuntary movement scale (AIMS). In ECDEU Assessment manual for psychopharmacology, revised National Institute of Mental Health.
Rockville, MD; 1976.
zORNI Test (Odor Recognition, Naming and Interpretation Test; developed for the purpose of odor testing in schizophrenics; manuscript in preparation)
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Page 4 of 20(n = 34) female subjects with an average age of 39.02 ±
13.87 years, ranging from 18 to 71 years.
Traveling team
The GRAS team of traveling investigators consisted of 1
trained psychiatrist and neurologist, 3 psychologists and
4 medical doctors/last year medical students. All investi-
gators had continuous training and calibration sessions
to ensure the highest possible agreement on diagnoses
and other judgments as well as a low interrater variabil-
ity regarding the instruments applied. Patient contacts
were usually prepared by colleagues/personnel in the
respective collaborating psychiatric centers (Figure 2) to
make the work of the travel team as efficient as possible.
The GRAS manual
A standardized procedure for examination of the
patients has been arranged with the GRAS manual,
composed for the purpose of the GRAS data collection.
Table 1 presents its contents, including established
instruments, such as clinical interviews/ratings, ques-
tionnaires, cognitive and neurological tests [2,29-53].
GRAS operating procedure
T h eG R A Sd a t ab a s eo p e r a t i n gp r o c e d u r el e a d i n gf r o m
the large set of raw data provided by the travel team
to the data bank with its several-fold controlled and
verified data points is illustrated in Figure 4. Already
during the time when the travel team examined
patients all over Germany, a team of psychologists
started to work on the development of the GRAS data
base, integrating the raw data to ultimately result in
over 3000 phenotypic data points per patient (total of
o v e r3 . 0 0 00 0 0d a t ap o i n t sa tp r e s e n ti nt h ed a t ac o l -
lection) (Figure 5). Most importantly, the chart
records/medical reports of all patients were carefully
screened, missing records identified and, in numerous,
sometimes extensive and repeated, telephone and writ-
ten conversations, missing psychiatric discharge letters
of every single patient organized. After careful study
and pre-processing of raw data and chart records, the
confirmation of the diagnoses, determination of age of
onset of the disease and prodrome as well as other
essential readouts were achieved by meticulous con-
sensus decisions.
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241 (22.2%) Bad Emstal-Merxhausen 1.
1085 total number of patients
48 (4.4%) Wunstorf 23.
27 (2.5%) Wilhelmshaven 22.
32 (2.9%) Taufkirchen 21.
80 (7.4%) Rostock 20.
91 (8.4%) Rieden 19.
56 (5.2%) Rickling 18.
53 (4.9%) Mühlhausen 17.
4 (0.4%) Moringen 16.
30 (2.8%) Lübbecke 15.
27 (2.5%) Liebenburg 14.
24 (2.2%) Langenhagen 13.
26 (2.4%) Kiel 12.
19 (1.8%) Kassel 11.
27 (2.5%) Ingolstadt 10.
10 (0.9%) Hofgeismar 9.
31 (2.9%) Günzburg 8.
114 (10.5%) Göttingen 7.
36 (3.3%) Giessen-Haina 6.
30 (2.8%) Fulda 5.
20 (1.8%) Eltville-Eichberg 4.
19 (1.8%) Bonn 3.
40 (3.7%) Bad Zwischenahn 2.
numbers of recruited patients center (city)
Figure 2 Collaborating centers and patient numbers. Map of Germany displaying the locations of all 23 collaborating centers that were
visited by an invariable team of traveling investigators. The table next to the map provides numbers of patients examined in each center. Some
centers were visited more than once.
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Page 5 of 20Statistical analyses
For the establishment of the data base and for basic sta-
tistical analyses of the data, SPSS for Windows version
17.0 [54] was used. Comparisons of men and women in
terms of sociodemographic and clinical picture as well
as neurological examination were assessed using either
Mann-Whitney-U or Chi-square test. Prior to correla-
tion and regression analyses, selected metric phenotypic
variables were standardized by Blom transformation
[55]. The Blom transformation is a probate transforma-
tion into ranks and the resulting standardized values are
normally distributed with zero mean and variance one.
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Figure 3 Patient recruitment and flow: (a) Recruitment efficiency 2005 - 2008. Cumulative numbers of recruited patients per quarter of the
year are shown in bar graphs. Note that steady-state recruitment is ongoing. (b) Patient flow. Of 1085 patients examined, the diagnosis of
schizophrenia or schizoaffective disorder could not be confirmed for 48. Instead, alternative diagnoses had to be given.
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Page 6 of 20Table 2 GRAS sample description
total men women statistics
N % mean (sd) median N % mean (sd) median N % mean (sd) median c
2/Z P
sociodemographics
total n 1037 100 693 100 344 100
age (in years) 39.52
(12.56)
39.05 37.57
(11.97)
36.67 43.46
(12.80)
42.85 Z = -6.980 <
0.001*
education
(in years)
11.94 (3.37) 12.00 11.71 (3.34) 12.00 12.42 (3.39) 12.00 Z = -2.714 0.007*
ethnicity: caucasian 992 95.66 661 95.38 331 96.20
african 7 0.68 6 0.87 1 0.30
mixed 10 0.96 7 1.01 3 0.90 c
2 = 1.202 0.753
unknown 28 2.70 19 2.74 9 2.60
native tongue: German 902 86.98 591 85.71 311 90.67
bi-lingual German 46 4.44 38 4.33 8 1.46 c
2 = 6.899 0.032*
other 89 8.58 64 9.96 25 7.87
marital status: single 748 72.13 575 82.97 173 50.44
married 129 12.44 48 6.93 81 23.32
divorced 124 11.96 57 8.23 67 19.53 c
2 =
121.516
<
0.001*
widowed 13 1.25 3 0.43 10 2.92
unknown 23 2.22 10 1.44 13 3.79
living situation: alone 292 28.16 201 29.00 91 26.45
alone with children 17 1.64 0 0 17 4.94
with partner (± children) 137 13.20 50 7.22 87 25.29
With parents 157 15.14 121 17.46 36 10.47
with others (family members,
friends)
71 6.85 53 7.65 18 5.23 c
2 =
116.823
<
0.001*
sheltered home 282 27.19 212 30.59 70 20.35
forensic hospital 54 5.21 43 6.20 11 3.20
homeless 4 0.39 4 0.58 0 0
unknown 23 2.22 9 1.30 14 4.07
clinical picture
diagnosis: classical schizophrenias
schizoaffective disorders
852
185
82.16
17.84
615
78
88.74
11.26
237
107
68.90
31.10
c
2=
61.794
<
0.001*
age of onset of first psychotic
episode
25.75 (8.81) 23.00 24.49 (7.71) 22.00 28.28
(10.23)
26.00 Z = -5.705 <
0.001*
duration of disease (in years) 13.23
(10.71)
10.87 12.57
(10.38)
10.16 14.54
(11.24)
13.02 Z = -2.600 0.009*
hospitalization (number of
inpatient stays)
8.60 (9.76) 6.00 8.49 (9.95) 5.00 8.83 (9.38) 6.00 Z = -0.727 0.467
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chlorpromazine equivalents 687.36
(696.85)
499.98 706.67
(668.43)
520.00 648.35
(750.50)
450.00 Z = -2.428 0. 015*
PANSS
a: positive symptoms 13.76 (6.32) 12.00 13.94 (6.16) 12.00 13.92 (6.64) 12.00 Z = -0.130 0.990
negative symptoms 18.23 (7.85) 17.00 18.14 (7.57) 17.00 18.11 (8.44) 17.00 0.886 0.376
general psychiatric symptoms 33.73
(11.83)
32.00 33.37
(11.31)
32.00 34.50
(12.81)
33.00 -0.886 0.376
total score 65.64
(23.40)
63.00 65.32
(22.41)
63.00 66.31
(25.37)
62.00 -0.025 0.980
Clinical Global Impression scale
b 5.57 6.00 5.57 (1.03) 6.00 5.57 (1.18) 6.00 Z = -0.121 0.894
Global Assessment of Functioning
c 45.76 (0.68) 45.00 45.60
(16.30)
45.00 46.09
(19.11)
45.00 Z = -0.323 0.747
global quality of life
d 5.41 (2.37) 5.00 5.43 (2.31) 5.00 5.38 (2.49) 5.00 Z = -0.378 0.705
Brief Symptom Inventory
e: general severity index 0.88 (0.68) 0.71 0.87 (0.66) 0.71 0.92 (0.72) 0.71 Z = -0.687 0.492
State-Trait-Anxiety Inventory
f : state anxiety 43.54
(10.89)
43.00 43.48
(10.45)
43.00 43.65
(11.79)
43.00 Z = -0.121 0.904
trait anxiety 44.96
(11.34)
45.00 44.67
(11.09)
45.00 45.56
(11.82)
46.00 -0.983 0.326
Toronto Alexithymia Scale
g 2.59 (0.56) 2.61 2.58 (0.54) 2.55 2.60 (0.60) 2.66 Z = -0.607 0.544
aKay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull1987,13(2):261-276.
bGuy W: Clinical Global Impressions (CGI). In ECDEU Assessment manual for
psychopharmacology, revised NationalInstitue of Mental Health. Rockville, MD; 1976.
cAmericanPsychiatricAssociation: Diagnostic and statistical manual of mental disorders, 4th edition (DSM-IV). Washington, DC:
American Psychiatric Press; 1994.
dBased on a visual analogue scale (Krampe H, Bartels C, Victorson D, Enders CK, Beaumont J, Cella D, Ehrenreich H: The influence of personality factors on disease progression and
health-related quality of life in people with ALS. Amyotroph Lateral Scler 2008, 9:99-107).
eFranke GH: Brief Symptom Inventory (BSI). Goettingen: Beltz; 2000.
fLaux L, Glanzmann P, Schaffner P, Spielberger CD: Das
State-Trait-Angstinventar (STAI). Weinheim: Beltz; 1981.
gKupfer J, Brosig B, Braehler E: Toronto Alexithymie-Skala-26 (TAS-26). Goettingen: Hogrefe; 2001.
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0Comparisons of men and women in terms of cognitive
p e r f o r m a n c ew e r ea s s e s s e db ya n a l y s e so fc o v a r i a n c e ,
using age, duration of disease, years of education and
chlorpromazine equivalents as covariates. For all inter-
correlation patterns, correlations of the particular target
variables were assessed using Pearson product-moment
correlation. Cronbach’s alpha coefficient was determined
for estimation of internal consistency of the target vari-
ables within a defined intercorrelation pattern. Multiple
regression analyses using the enter method were con-
ducted to evaluate the contribution of selected disease
related variables (duration of disease, positive symptoms,
negative symptoms, catatonic signs and chlorpromazine
equivalents) to 3 dependent variables: basic cognition/
fine motor functions, cognitive functions and global
functioning (GAF) [2]. The dependent variables basic
cognition/fine motor functions and cognitive functions
are both composite score variables. The basic cognition/
fine motor function score comprises alertness (TAP),
dotting and tapping (Cronbach’s alpha = .801) [39,46]
and the cognition score consists of reasoning (LPS3), 2
processing speed measures (TMT-A and digit-symbol
test, ZST), executive functions (TMT-B), working mem-
ory (BZT), verbal learning & memory (VLMT) and
divided attention (TAP) [37,38,41,44-46] (Cronbach’s
alpha = .869). For both scores, a Cronbach’s alpha >.80
indicates a high internal consistency as prerequisite for
integrating several distinct items into one score. Multi-
p l er e g r e s s i o na n a l y s e sw e r ec o n d u c t e df o rt h et o t a l
sample and separated for men and women.
Results
Biographic and clinical data
The GRAS data collection comprises presently (as of
August 2010) 1037 patients with confirmed diagnosis of
schizophrenia (82.2%) or schizoaffective disorder
(17.8%). A total of 693 men and 344 women fulfilled the
respective diagnostic requirements of DSM-IV. Table 2
provides a sample description, both total and separated
for male and female patients, with respect to sociode-
mographic data and clinical picture. There are some dif-
ferences between genders in the GRAS sample: Women
are older, less single, have more years of education,
more diagnoses of schizoaffective disorders, longer dura-
tion of disease, later age of onset of first psychotic epi-
sode and lower doses of antipsychotics. However,
regarding determinants of the clinical picture, e.g.
PANSS scores [30], genders do not differ significantly.
raw data
from
travel team
meticulous double-check of entered data
confirmation of consensus diagnosis based on 
chart records (e.g. first diagnosis, first psychotic 
episode, current diagnosis, differential diagnosis)
determination of age of onset, duration of 
prodromal symptoms, medication history, pattern 
of course, psychiatric and medical comorbidity
continuous training and calibration sessions
of all raters and research assistants
analysis and entering of questionnaire data, rating 
scales and neuropsychological tests
collection of all
psychiatric  
discharge
letters of every 
single patient
careful study & 
preprocessing of 
all collected 
information
result:
data bank of 
> 3,000,000
phenotypic
data points
screening of 
chart records/ 
medical reports,
identification of 
missing records
Figure 4 Development of the GRAS data bank. Raw data, brought to Göttingen by the traveling team of examiners, were only entered into
the data base after careful and comprehensive data re-checking, also based on patient charts and discharge letters. During the whole process,
continuous calibration sessions and repeated re-checking of the entered data took place.
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Page 9 of 20An intercorrelation pattern of selected clinical readouts,
obtained by (1) clinical ratings and (2) self-ratings of the
patients and complemented by (3) ‘objective data’,i n
this case medication and hospitalization, is presented in
Figure 6. The Cronbach’s alpha of .753 suggests that
items derived from the 3 different perspectives harmo-
nize well. Whereas patient ratings of quality of life and
state anxiety (STAI) [32] are only weakly correlated with
professional clinical ratings and objective data, the
patients’ self-estimated symptom burden as measured
with the BSI [33] shows moderate to good correlation.
Cognition
For the ongoing/planned genetic analyses, not only the
clinical picture with its schizophrenia-typical positive
and negative symptoms, but particularly cognition plays
an important role. The cognitive tests applied in the
GRAS data collection show an intercorrelation pattern
that further underlines quality and internal consistency
of the data obtained by the invariable team of investiga-
tors (Figure 7). Table 3 represents the cognitive perfor-
mance data of the complete GRAS sample in the
respective domains. In addition, the performance level
of men and women is given as well as - for comparison
- available normative data of healthy individuals. Since
for dotting and tapping [39], no normative data were
available in the literature, the values shown in Table 3
were obtained from the healthy GRAS control popula-
tion for cognitive measures (n = 103; see patients and
methods).
Comparing cognitive performance of schizophrenic
men and women, analyses of covariance have been con-
ducted, with age, duration of disease, years of education
and chlorpromazine equivalents as covariates, which
revealed significant gender differences in discrete cogni-
tive domains. Men performed better in reasoning (F =
17.62, p <.001), alertness (F = 28.30, p <.001 for reaction
time and F = 10.39, p = .001 for lapses), and divided
attention (F = 14.07 p <.001 for reaction time and F =
22.12, p <.001 for lapses). In contrast, female schizo-
phrenic patients were superior in verbal memory tasks
(F = 12.38, p <.001) and digit symbol test (F = 19.24, p
<.001). With respect to normative data obtained from
h e a l t h yc o n t r o l s ,c o g n i t i v ed a t ao fa l ls c h i z o p h r e n i c
patients are in the lower normal range (percentile rank
= 16 for digit symbol test) or even below (percentile
f family history: prevalence of 
spectrum disorders…
sociodemographic characteristics:
education, training, forensic information…
psychopathology: psychiatric ratings, subjective symptoms, course, 
diagnostic categories, hallucination and delusion phenomena…
neurological examination: neurological standard exam, 
soft signs, odor testing, saccadic eye movements…
neuropsychology / cognition: speed of processing, attention / vigilance, 
working memory, verbal learning, reasoning / problem solving (executive functioning), motor 
function, crystalline / fluid intelligence…
birth complications: prolonged birth, 
asphyxia, premature birth…
psychiatric comorbidity: anxiety, depression, mania, 
substance abuse, e.g. alcohol, cannabis… 
medication history: type, combination, 
dose of antipsychotic medication during 
disease course, side effects...
physical examination:
minor abnormalities, comorbidity… social functioning: living skills, employment, 
social network, quality of life…
disease history: age of onset, duration of 
prodromal symptoms, first diagnosis, first 
psychotic episode…
neuro- and psychotrauma: cerebral contusion, 
loss of consciousness, abuse during childhood, migration…
phenotype
overview
hospitalization: number and duration 
of psychiatric inpatient stays and forensic stays…
Figure 5 Phenotype overview. Various different domains covered by the GRAS data collection are displayed. These domains will also deliver
the basis for further sophistication of phenotypical readouts.
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Page 10 of 20ranks 10 for verbal memory, TMT-A, TMT-B, alertness
and divided attention). Only for reasoning (LPS) [37]
and premorbid intelligence (MWT-B) [36], schizophre-
nic subjects lie in the average range (percentile ranks of
31 and 43.5 respectively).
Antipsychotic medication and side effects
Another important feature of schizophrenic patients that
may influence their every-day functioning and perfor-
mance, and result in a considerable number of side effects,
is their antipsychotic medication. The GRAS data collec-
tion contains information on type, dose, duration of medi-
cation and drugs prescribed over the years. The mean
dose of present antipsychotic medication of the whole
GRAS population, expressed as chlorpromazine equiva-
lents [56] amounts to 687.36 (± 696.85). Chlorpromazine
equivalents in male are significantly higher as compared to
female patients (Table 2). An overview of self-reported
side effects of current antipsychotic medication in the
GRAS sample, again sorted by gender, is given in Table 4.
Of the 1037 patients with confirmed diagnosis of schizo-
phrenia/schizoaffective disorder, 24 were presently not on
antipsychotic drugs, whilst for 1 patient the current medi-
cation was unknown. Of the remaining 1012 patients who
currently receive antipsychotic medication (16.5% first
generation antipsychotics, 54.1% second generation anti-
psychotics and 29.4% mixed) and were all explicitly inter-
viewed regarding medication side effects, only 423
reported any. The discrepancy between side effects mea-
sured versus side effects based on patients’ reports
becomes obvious when considering for instance the num-
ber of patients with clear extrapyramidal symptoms: A
total of 335 subjects measured by Simpson-Angus Scale
(mean score >.3) [50] contrasts only 117 patients self-
reporting extrapyramidal complaints. External rating of
extrapyramidal side effects in the GRAS population was
comprehensively performed, utilizing a number of respec-
tive instruments which all showed significant
self ratings (patients) clinical ratings
objective data
Cronbach's alpha=.753
state anxiety
STAI
general 
psychopathology
PANSS
global 
assessment 
of functioning
GAF
r < .3 .3 < r < .6 .6 < r < .9 
medication
current
CPZ-equivalents
hospitalization
number of 
inpatient stays
quality of life
current
clinical global
impression
CGI
symptom burden
BSI-GSI
Figure 6 Clinical intercorrelation pattern. Correlations between measures of the clinical picture derived from different approaches: Patient
self-ratings, clinical rater judgement and ‘objective data’. Thickness of the lines represents the strength of correlation between two measures;
only significant correlations are displayed. Note the strong internal consistency expressed by a Cronbach’s alpha of .753.
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Page 11 of 20intercorrelation (Figure 8) [47,49-52,57]. A composite
score of the 6 Blom transformed scales, used for testing
potential gender effects, yielded no significant differences
in extrapyramidal symptoms in men versus women (Z =
-0.022, p = 0.982).
Neurological symptoms
Similar to cognitive readouts, evaluation of inherent
neurological symptoms in the schizophrenic patient
population are of tremendous interest, not only for
understanding the contribution of particular genes/
genetic markers and/or environmental factors to the
schizophrenic phenotype but also for estimating the
impact of potential neurological comorbidities. Table 5
provides an overview of neurological symptoms based
on the Cambridge Neurological Inventory (CNI) [47].
Only in the subscale ‘Failure to suppress inappropriate
response’, significant differences between men and
women (Z = -3.175, p = 0.001) became evident. Women
were less able to hold respective responses back, e.g. to
blink with one eye, leaving the other eye open, or to
perform saccadic eye movements without moving the
head.
Prediction of functioning
In order to delineate the influence of disease on func-
tioning in the GRAS sample, multiple regression ana-
lyses have been employed. These procedures assessed
the contribution of 5 disease-related variables, i.e. dura-
tion of disease, PANSS positive and negative scores [30],
catatonic signs [47], and dose of antipsychotic medica-
tion, to 3 dependent performance variables: (a) basic
cognition/fine motor functions, (b) cognitive perfor-
mance and (c) global functioning (Table 6). Regarding
basic cognition/fine motor function, multiple regression
analysis revealed a significant model accounting for
processing
speed
ZST
r < .3 .5 < r < .6
fine motor
tapping
alertness
TAP
fine motor
dotting
premorbid IQ
MWT-B
verbal memory
VLMT
.3 < r < .5
working
memory
BZT executive 
functions
TMT-B
processing
speed
TMT-A
divided
attention
TAP
reasoning
LPS3
basic cognition/ 
fine motor functions
Cronbach's alpha =.801
cognitive  functions
Cronbach's alpha =.819
.6 < r < .9
Figure 7 Cognitive intercorrelation pattern. Shown are all neuropsychological tests performed, together with their respective cognitive
domain. Thickness of the lines represents the strength of correlation between two tests; only significant correlations are displayed. Tests for
higher cognitive functions are labelled in orange; tests for basic (mainly basic cognition/fine motor dependent) functions in grey. Measures of
higher cognitive functions as well as measures of basic cognition/fine motor functions show powerful internal consistency (Cronbach’s alpha of
.819 and .801 respectively).
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Page 12 of 2032.4% of variance in the total sample. In fact, duration
of disease, negative symptoms, catatonic signs, and med-
ication (chlorpromazine equivalents) contributed signifi-
cantly to basic cognition/fine motor function, whereas
positive symptoms did not (b = -.006, p = .856). Accord-
ing to the standardized regression coefficients, duration
of disease and negative symptoms are the best
predictors of basic cognition/fine motor function (b =
-.346, p < .001 and b = -.334, p < .001). For higher cog-
nitive functions, the set of disease-related variables
explained 33% of variance in the total sample. Again,
duration of disease and negative symptoms are the best
predictors of higher cognitive functions (b = -.335, p <
.001 and b = -.351, p < .001). Positive symptoms did not
Table 3 Cognitive performance of GRAS patients. For comparison, normative data are presented wherever available2.
men women ANCOVA total normative data (PR) or
mean
sample
values of healthy
controls
N mean
(sd)
median N mean
(sd)
median F p N mean
(sd)
median N PR
(Percentile
Rank)
mean
(sd)
reasoning (LPS) 663 21.26
(6.70)
22.00 324 18.79
(6.31)
18.00 17.62 <
.001*
987 20.45
(6.67)
21.00 1556
a 31 -
working memory (BZT) 627 13.24
(3.79)
14.00 312 12.62
(3.91)
13.00 1.20 .274 939 13.03
(3.84)
13.00 30
b - 15.70
(2.6)
executive functions
(TMT-B)°
631 131.42
(104.21)
99.00 307 147.65
(121.09)
108.00 0.00 .956 938 136.73
(110.22)
100.00 24
c 10 71.5
(31.07)
verbal memory
1)
(VLMT)
602 41.15
(12.63)
41.00 302 42.68
(13.02)
42.00 12.38 <
.001*
904 41.66
(12.78)
42.00 89
d 10 52.39
(7.87)
premorbid IQ
1)(MWT-B) 613 25.96
(6.22)
27.00 311 26.21
(6.13)
27.00 0.69 .405 924 26.04
(6.19)
27.00 1952
e 43.5 -
divided attention
(TAP)°
reaction time 651 759.67
(114.25)
743.43 308 805.16
(150.99)
780.04 14.07 <
.001*
959 774.28
(128.89)
755.05 200
f 8-
lapses 3.35
(7.15)
1.00 6.41
(13.18)
2.00 22.12 <
.001*
4.33
(9.62)
1.00
processing speed
trail making test A
(TMT-A)°
676 49.18
(35.22)
40.00 332 55.32
(42.22)
43.00 0.17 .683 1008 51.20
(37.76)
41.00 24
c < 5 33.04
(7.89)
digit-symbol test
(ZST)
674 37.46
(12.58)
37.00 329 38.58
(14.14)
39.00 19.24 <
.001*
1003 37.83
(13.12)
38.00 200
g 16 -
basic cognition/fine
motor function
alertness (TAP)°
reaction time 665 319.62
(116.13)
284.08 326 379.11
(161.80)
328.04 28.30 <
.001*
991 339.19
(135.73)
298.41 200
f 10 -
lapses 0.52
(2.04)
0.00 1.18
(3.57)
0.00 10.39 .001* 0.73
(2.66)
0.00
dotting 673 46.10
(13.08)
46.00 320 45.36
(14.96)
46.00 1.62 .203 993 45.86
(13.71)
46.00 103
h - 63.24
(11.03)
tapping 671 29.01
(8.57)
29.00 319 27.58
(9.00)
27.00 0.76 .783 990 28.55
(8.73)
28.00 103
h - 37.63
(7.04)
° Higher scores reflect better performance, except for TMT-A, TMT-B, Alertness and Divided Attention (TAP)
* For statistical comparison (ANCOVA) between men and women values are corrected for age, duration of disease, chlorpromazine equivalents and years of
education (except MWT-B).
1) Non-native and non-bilingual German speaking patients are excluded (n = 89).
2) Percentile ranks (PR) < 15 indicate that the mean or the median of the total sample is below average in comparison to a normative sample.
aHorn W: Leistungsprüfsystem (LPS). 2 edition. Goettingen: Hogrefe; 1983.
bGold JM, Carpenter C, Randolph C, Goldberg TE, Weinberger DR: Auditory working
memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry 1997, 54(2):159-165.
cPerianez JA, Rios-Lago M, Rodriguez-Sanchez
JM, Adrover-Roig D, Sanchez-Cubillo I, Crespo-Facorro B, Quemada JI, Barcelo F: Trail Making Test in traumatic brain injury, schizophrenia, and normal ageing:
sample comparisons and normative data. Arch Clin Neuropsychol 2007, 22(4):433-447.
dHelmstaedter C, Lendt M, Lux S: Verbaler Lern- und Merkfähigkeitstest
(VLMT). Goettingen: Beltz; 2001.
eLehrl S: Mehrfach-Wortschatz-Intelligenztest MWT-B. Balingen: Spitta Verlag; 1999.
fZimmermann P, Fimm B: Testbatterie zur
Aufmerksamkeitsprüfung (TAP). Version 1.02c. Herzogenrath: PSYTEST; 1993.
gTewes U: Hamburg-Wechsler Intelligenztest fuer Erwachsene (HAWIE-R). Bern: Huber;
1991.
hHealthy controls recruited for selected cognitive and olfactory testing (unpublished data).
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Page 13 of 20reach significance (b = - .015, p = .658). With respect to
global functioning, all chosen disease-related factors
accounted for 59.6% of variance in the total sample.
Only duration of disease per se did not reach signifi-
cance (b = -.028, p = .198). Positive and negative symp-
toms were the strongest predictors of global functioning
(b = - .441, p < .001 and b = -.380, p < .001).
Discussion
The present paper provides an overview of the GRAS
data collection, including (1) study logistics and proce-
dures, (2) sample description regarding sociodemo-
graphic data, disease-related variables, cognitive
performance and neurological symptoms, paying parti-
cular attention to gender differences, and (3) a first pre-
sentation of intercorrelation patterns for selected areas
of interest to phenotype studies. (4) In addition, disease-
related factors influencing important criteria of daily
functioning are evaluated in the >1000 GRAS patients.
Overall, the GRAS sample represents a typical schizo-
phrenic population in contact with the health system
and is - last not least due to its homogeneous data
acquisition - ideally suited for the ongoing and planned
phenotype-based genetic association studies (PGAS) (e.g.
[[11], and Grube et al: Calcium-activated potassium
channels as regulators of cognitive performance in schi-
zophrenia, submitted]).
The GRAS data collection has several remarkable
advantages, two of which are of major importance for
its ultimate goal, PGAS: (i) Different from other studies
dealing with the establishment of a schizophrenia data
base, all data for GRAS were collected by one and the
same traveling team of examiners, who frequently per-
formed calibrating sessions and rater trainings. This
effort has clearly paid off in terms of reliability and qual-
ity of the data, considering the internal consistencies of
the GRAS phenotypes, as exemplified in the displayed
correlation patterns. (ii) Even though the GRAS study
has been implemented as a cross-sectional investigation,
the GRAS data collection also includes solid longitudinal
information derived from the almost complete psychia-
tric chart records/discharge letters of all schizophrenic
patients. This longitudinal set of data has been essential
to e.g. reliably estimate prodrome versus disease onset, i.
e. occurrence of the first psychotic episode.
Comparable to other schizophrenia samples, the
GRAS sample comprises around two thirds of male and
one third of female patients [17,58]. Assuming that the
gender ratio in schizophrenia were 1:1 as claimed in
text books, but recently also questioned [59,60], then
two principal reasons may account for the gender distri-
bution observed here: (1) Schizophrenic women gener-
ally seem to have less contact with the health system
due to being better socially settled (later age of onset of
Table 4 Self-reported medication side effects of patients (N = 423)* according to treatment type
FGA
1 SGA
2
men women men women
Parkinson symptoms 17% 15.6% 3.8% 11.6%
dyskinetic/dystonic symptoms 35.8% 31.3% 9.4% 9.7%
akathisia 22.6% 12.5% 6% 6.8%
hyperprolactinaemia - - - 1.9%
hormonal dysfunctions (gynecomastia, absence/changes of menorrhea) - 9.4% - 5.8%
sexual dysfunction 7.5% - 10.3% -
vertigo (incl. hypotonia) 5.7% 12.5% 5.1% 8.7%
weight gain 9.4% 18.7% 38.3% 39.8%
diabetes mellitus - - 0.4% -
sialorrhea (’drooling’) - - 20.4% 6.8%
skin abnormalities, loss of hair 1.9% - 1.7% 5.8%
gastrointestinal symptoms 1.9% 6.3% 5.9% 7.8%
hyperhidrosis - - 2.6% -
psychological symptoms (loss of concentration, no drive, tiredness) 33.9% 28.1% 44.2% 31.1%
cardiovascular symptoms (tachycardia, hypertension) - - 1.3% 1.9%
impaired vision - - 1.7% 3.9%
dry mouth 5.7% 9.4% 5.1% 4.9%
urinary retention - 3.1% 1.3% -
number of patients who reported side effects 53 32 235 103
1FGA - first generation antipsychotics, typical antipsychotics
2SGA - second generation antipsychotics, atypical antipsychotics
*Only N = 423 patients (out of 1012 patients who were on antipsychotic medication) reported side effects (see text for details).
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Page 14 of 20disease) and protected within their families [61]; (2) A
certain (smaller) recruitment bias may be explained by
the fact that the traveling team of examiners visited
some institutions with an overrepresentation of males, e.
g. specialized forensic units or a hospital for psychotic
patients with co-morbid substance use disorders.
With the purposeful strategy to visit several different
facilities of psychiatric health care covering inpatients,
outpatients, residents of sheltered homes and forensic
patients, the GRAS approach tried to avoid biases inher-
ent to pure inpatient samples [58]. Nevertheless, patients
who are not in contact with the health care system are
unlikely to be integrated in any comparable data bases.
For instance, only 4 of the 1085 examined patients are
currently homeless, whereas among homeless people a
considerable proportion suffers from schizophrenia [62].
To reach them as well, different and more cost intensive
recruitment strategies would be required [13]. On the
other hand, the schizophrenic phenotype required for
the GRAS-PGAS studies pursued here, might be veiled
in this severely affected subsample of patients that is
additionally characterized by other specific problems, e.
g. a highly elevated incidence of multiple substance use
disorders and severe downstream medical comorbidities
[63,64].
Gender differences in schizophrenia as obvious from
the present data collection have been known for a long
time [65]. In agreement with the literature, men and
women in the GRAS sample differ by diagnosis, with
women having a higher rate of schizoaffective disorders
[66,67]. With respect to age of onset, education, indica-
tors of social integration (e.g. marital status, living situa-
tion) and medication, the present results are also in
perfect agreement with previous findings: Male patients
Parkinsonism
Tardive Dyskinesia
Barnes Akathisia 
Rating Scale
Tardive Dyskinesia 
Rating Scale
Simpson-Angus
Scale
Abnormal
Involuntary
Movement Scale
r < .3 .3 < r < .6 .6 < r < .9
TDRS
SAS
AIMS
BARS
CNI sub-scale
CNI sub-scale
Cronbach's alpha =.675
Figure 8 Extrapyramidal intercorrelation pattern. Shown are correlations between different neurological tests for measuring extrapyramidal
symptoms. Thickness of the lines represents the strength of correlation between two tests; only significant correlations are displayed. Cronbach’s
alpha of .675 shows that these measures have a decent internal consistency.
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Page 15 of 20are younger when the first psychotic episode occurs, are
more frequently single, more often dependent on sup-
ported living conditions (e.g. residential homes) and
show lower educational status [61,67,68]. Among the
explanations for the observed gender differences in schi-
z o p h r e n i aa r et h ep r o t e c t i v er o l eo ff e m a l eh o r m o n e s
[69] and social aspects like earlier marriage of young
women leading to a more protected environment at dis-
ease onset [13]. In line with these considerations is the
work of Häfner and colleagues [12]. In a prospective
design he could show that ‘t h es o c i a lc o u r s e( o fs c h i z o -
phrenia) is determined by individual stage at illness
onset and by early illness course’ [70].
With respect to psychopathology and premorbid func-
tioning, the GRAS sample may be slightly different from
other schizophrenia samples reported in the literature
[67]. Several studies published in this area show that men
exhibit more negative symptoms, even in a geriatric sam-
ple [71,72], and that females have poorer premorbid cogni-
tive functioning than males [73]. In the GRAS patients,
there are no gender differences regarding psychopathology
and premorbid cognition. Importantly, clear support for a
comparable severity of psychopathology in men and
women of the GRAS sample is provided by the lack of
gender differences in numbers of hospitalizations, clinical
severity ratings, including global functioning (CGI, GAF
[2,31]), and self-ratings of symptom severity and anxiety.
One potential explanation for the discrepancies between
the GRAS sample and other studies regarding psycho-
pathology may be that patient numbers in some of the
other studies have been too low to give conclusive results.
In the assessment of premorbid cognitive functioning of
the GRAS sample, a methodological limitation could be
the retrospective determination of premorbid intelligence
using a so-called ‘hold’ measure, i.e. a multiple choice
vocabulary test [35]. Even though this is an accepted and
valid instrument to retrospectively estimate premorbid
intelligence [74], a prospective procedure might be more
accurate. In fact, Weiser and colleagues had the opportu-
nity to base their assessments on cognitive testing per-
formed on adolescents before starting their military
service [73], potentially explaining the deviating results.
Gender differences regarding current cognitive perfor-
mance are similar within the GRAS sample (even though
Table 5 Cambridge Neurological Inventory (CNI)a subscale sum scores (N = 893-942)
total men women statistics
sub scales Mean
(sd)
Median
(range)
Mean
(sd)
Median
(range)
Mean
(sd)
Median
(range)
Zp
Hard neurological signs
plantar reflexes (le/ri*), power in upper and lower limb (le/ri), and reflexes
(hyper- and hyporeflexia) in upper and lower limb (le/ri)
1.12
(1.70)
0.0 (0 -
10)
1.07
(1.66)
0.0 (0-8) 1.22
(1.78)
0.0 (0-
10)
-1.467 n.s
Motor coordination
finger-nose test (le/ri), finger-thumb tapping (le/ri), finger-thumb opposition
(le/ri), pronation-supination (le/ri); fist-edge-palm test (le/ri), Oseretsky test
4.11
(4.27)
3.0 (0-
20)
3.95
(4.17)
2.0 (0-
20)
4.44
(4.45)
3.0 (0-
20)
-1.629 n.s
Sensory integration
extinction, finger agnosia (le/ri), stereoagnosia (le/ri), agraphesthesia (le/ri),
left-right disorientation
3.66
(3.32)
3.0 (0-
15)
3.63
(3.32)
3.0 (0-
15)
3.73
(3.31)
3.0 (0-
14)
-0.521 n.s
Primitive reflexes
snout reflex, grasp reflex, palmo-mental reflex (le/ri) 0.84
(1.14)
0.0 (0-5) 0.80
(1.11)
0.0 (0-5) 0.91
(1.19)
0.0 (0-5) -1.363 n.s
Tardive dyskinesia
dyskinetic, sustained or manneristic face and head movement, simple or
complex abnormal posture, dyskinetic, dystonic or manneristic trunk/limb
movement
0.55
(1.17)
0.0 (0-9) 0.58
(1.25)
0.0 (0-9) 0.49
(0.98)
0.0 (0-7) -0.132 n.s
Catatonic signs
gait mannerism, gegenhalten, mitgehen, imposed posture, exaggerated or
iterative movement, automatic obedience, echopraxia
0.43
(0.96)
0.0 (0-8) 0.45
(0.98)
0.0 (0-8) 0.38
(0.91)
0.0 (0-7) -1.717 n.s
Parkinsonism
increased tone in upper and lower limb (le/ri), decreased associated
movements in walking, shuffling gait, arm dropping, tremor postural or
resting, rigidity in neck
1.76
(2.90)
0.0 (0-
15)
1.70
(2.85)
0.0 (0-
15)
1.89
(3.02)
0.5 (0-
15)
-1.172 n.s
Failure to suppress inappropriate response
blinking or head movement in saccadic eye movement, winking with one
eye
1.23
(1.49)
1.0 (0-6) 1.12
(1.42)
1.0 (0-6) 1.48
(1.62)
1.0 (0-6) -3.175 .001*
*le/ri - left and right
aChen EY, Shapleske J, Luque R, McKenna PJ, Hodges JR, Calloway SP, Hymas NF, Dening TR, Berrios GE: The Cambridge Neurological Inventory: a clinical
instrument for assessment of soft neurological signs in psychiatric patients. Psychiatry Res 1995, 56(2):183-204.
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Page 16 of 20at a lower functioning level [75]) compared to healthy con-
trols [76] after considering age of onset, duration of dis-
ease, education and medication as covariates. Men
perform better in reasoning, alertness and divided atten-
tion but worse in verbal memory, confirming reports on
first-episode as well as chronically ill schizophrenic
patients [77].
Women in the GRAS study receive significantly lower
doses of chlorpromazine equivalents, confirming that
they require less medication to achieve a reasonable
treatment effect [78]. Importantly, regarding medication
side effects, there were no gender differences in extra-
pyramidal symptoms. There were also no differences in
the overall proportion of men and women who self-
reported side effects, but the pattern of complaints was
slightly different. For instance, women mentioned more
often hormonal dysfunction and vertigo (or related
symptoms like hypotonia), whilst men complained
mainly about sexual dysfunction. Altogether, it is worth
pointing out that the percentage of patients self-report-
ing side effects is low when compared to that with
objectively measured side effects, e.g. extrapyramidal
symptoms (11.3% versus 32.3%).
Explicit studies on gender differences in antipsychotic
medication side effects found a somewhat different dis-
tribution of complaints, e.g. more weight gain, diabetes
and specific cardiovascular diseases in females [78,79].
Here, one reason is certainly the still preliminary data
set of the GRAS collection evaluated, based at this point
exclusively on cross-sectional patient reports. For a
more appropriate coverage of medication side effects, all
charts/discharge letters of every GRAS patient (also of
those patients who did/could not report them), will have
to be screened and entered into the data base. Compre-
hensive information on antipsychotic (and other) drugs
and their side effects in the GRAS sample has been col-
lected and is waiting for analyses to support e.g. future
pharmacogenomic approaches, perhaps also in colla-
boration with industry partners.
In line with the findings of a recent meta-analysis [80],
positive symptoms of the GRAS patients do not influ-
ence higher cognitive function or basic cognition/fine
Table 6 Multiple regression analyses predicting a) basic cognition/fine motor functions, b) cognitive performance, c)
global functioning
total male female
b tp b tp b tp
a) basic cognition/fine motor functions
1
duration of disease (years) -.346 -11.92 < .001 -.353 -9.68 < .001 -.318 -6.59 < .001
positive symptoms (PANSS) -.006 -0.18 .856 -.028 -0.69 .489 .065 1.08 .283
negative symptoms (PANSS) -.334 -10.05 < .001 -.293 -7.32 < .001 -.415 -7.01 < .001
catatonic signs (CNI) -.126 -4.26 < .001 -.128 -3.45 .001 -.161 -3.27 .001
medication (CPZ-equivalents) -.080 -2.70 .007 -.066 -1.83 .068 -.147 -2.84 .005
regression model r
2 = .324
p < .001
r
2 = .306
p < .001
r
2 = .383
p < .001
b) cognitive performance
2
duration of disease (years) -.335 -11.54 < .001 -.356 -9.72 < .001 -.294 -6.12 < .001
positive symptoms (PANSS) -.015 -0.44 .658 -.033 -0.80 .427 .023 0.38 .704
negative symptoms (PANSS) -.351 -10.47 < .001 -.320 -7.92 < .001 -.396 -6.56 < .001
catatonic signs (CNI) -.132 -4.46 < .001 -.103 -2.76 .006 -.204 -4.16 < .001
medication (CPZ-equivalents) -.082 -2.74 .006 -.060 -1.62 .105 -.140 -2.70 .007
regression model r
2 = .330
p < .001
r
2 = .305
p < .001
r
2 = .394
p < .001
c) global functioning
3
duration of disease (years) -.028 -1.29 .198 -.008 -0.28 .780 -.062 -1.78 .076
positive symptoms (PANSS) -.441 -17.33 < .001 -.458 -14.45 < .001 -.415 -9.60 < .001
negative symptoms (PANSS) -.380 -15.02 < .001 -.345 -10.97 < .001 -.430 -10.0 < .001
catatonic signs (CNI) -.060 -2.67 .008 -.050 -1.71 .088 -.093 -2.58 .011
medication (CPZ-equivalents) -.106 -4.71 < .001 -.122 -4.29 < .001 -.078 -2.07 .040
regression model r
2 = .596
p < .001
r
2 = .559
p < .001
r
2 = .662
p < .001
1A basic cognition/fine motor composite score was used as a dependent variable comprising alertness (TAP), tapping, and dotting (Chronbachs alpha = .801).
2A cognitive composite score was used as a dependent variable consisting of reasoning (LPS3), 2 processing speed measures (TMT -A and digit-symbol test, ZST),
executive functions (TMT-B), working memory (BZT), verbal memory (VLMT) and divided attention (TAP) (Chronbachs alpha = .869).
3Global assessment of functioning (GAF) was used as a dependent variable.
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Page 17 of 20motor performance, whilst negative symptoms, catatonic
signs, duration of disease and antipsychotic medication
have a significant effect on both. The clinical ratings of
global functioning, however, strongly rely on positive as
well as negative symptoms, medication and catatonic
signs [81-83].
Conclusion
GRAS enables a novel phenotype-based approach to
understand the molecular-genetic architecture of schizo-
phrenia. The GRAS data collection encompasses a large
sample of comprehensively phenotyped, moderately to
severely affected schizophrenic patients. Proof-of-princi-
ple for the suitability of the GRAS data collection for
PGAS has already been demonstrated [[11], and Grube
et al: Calcium-activated potassium channels as regula-
tors of cognitive performance in schizophrenia, sub-
mitted]. Further extensive analyses of the accumulated
information on every single patient are ongoing.
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